OncoMatch/Clinical Trials/NCT06207734
Discontinuation of CDK4/6 Inhibitors in Patients With Metastatic HR Positive, HER2 Negative Breast Cancer
Is NCT06207734 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments for breast cancer.
Treatment: Continuation of CDK4/6 inhibitor Palbociclib · Discontinuation of CDK4/6 inhibitor Palbociclib · Continuation of CDK4/6 inhibitor -Palbociclib · Discontinuation of CDK4/6 inhibitor -Palbociclib · Continuation of CDK4/6 inhibitor Abemaciclib · Discontinuation of CDK4/6 inhibitor Abemaciclib — This is a low-intervention, randomized, non-comparative, open-label, multicenter, prospective, phase II trial investigating discontinuation of CDK4/6 inhibitors in patients with metastatic HR positive, HER2 negative breast cancer with durable disease control.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Biomarker criteria
Required: ESR1 overexpression (positive)
estrogen receptor positive (ER+)
Required: HER2 (ERBB2) wild-type (negative)
HER2 negative (HER2-)
Disease stage
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: CDK4/6 inhibitor — plus endocrine therapy for at least 12 months with disease control
treated with CDK4/6 inhibitor plus endocrine therapy for at least 12 months with disease control (complete remission, partial remission or stable disease)
Lab requirements
Blood counts
hemoglobin > 9.0 g/dl; absolute neutrophil count judged as appropriate for study therapy by the investigator; platelets ≥ 100 x 10^9/l
Kidney function
calculated creatinine clearance judged as appropriate for study therapy by the investigator
Liver function
ast (sgot) / alt (sgpt) and alkaline phosphatase ≤ 2.5x uln; serum albumin > 30 g/l
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify